Hirokazu Okayama

19PUBLICATIONS
21CO-AUTHORS
Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Photochemistry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jun 26, 2026
Prognostic Factors for Cancer-Specific Survival after Recurrence in Chemo-Naïve Stage I-III Colorectal Cancer.

|May 18, 2026
Prognostic Impact of Histologic Subtypes in Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer: A Single-Center Retrospective Study of 1127 Stage 0-IV Patients.

|Jan 10, 2026
Evaluation of NTRK Fusions Detection Method in Esophageal Squamous Cell Carcinoma and Gastric Adenocarcinoma.

Tomoyuki Momma, Motonobu Saito, Shotaro Nakajima

|Nov 27, 2025
KRAS G12A Identifies a High-Risk Subset in Resected Stage II-III Colorectal Cancer.

Tomoyuki Momma, Hirokazu Okayama, Sohei Hayashishita

|Aug 18, 2025
GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression.

Hiroya Suzuki, Hirokazu Okayama, Shotaro Nakajima

|Aug 13, 2025
Residual Tumor Resection After Anti-PD-1 Therapy: A Promising Treatment Strategy for Overcoming Immune Evasive Phenotype Induced by Anti-PD-1 Therapy in Gastric Cancer.

Hajime Matsuida, Kosaku Mimura, Shotaro Nakajima

Pageof 4

Frequent Collaborators

12 joint publications

Motonobu Saito

10 joint publications

Kosaku Mimura

8 joint publications

Shotaro Nakajima

4 joint publications

Wataru Sakamoto